Qiang Liu
Professor
Biochemistry and Molecular Biology
Dalian Medical University
China
Biography
1989 Nanjing University, P. R. China, B.S. 1997 University of Illinois at Urbana-Champaign, Ph.D. 1998 University of Illinois at Urbana-Champaign, Postdoc 2000 University of Illinois at Chicago, M.D 2003 Mount Sinai hospital, New York, Resident 2006 Harvard Medical School, Research Fellow
Research Interest
Biochemistry and Molecular Biology
Publications
-
Hou Z J, Luo X, Zhang W, Peng F, Cui B, Wu S J, Zheng F M, Xu J, Xu L Z, Long Z J, Wang X T, Li G H, Wan X Y, Yang Y L, Liu Q*(2015). Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget. (IF: 6.627).6(8):6326-6340.
-
Hou Z J, Luo X, Zhang W, Peng F, Cui B, Wu S J, Zheng F M, Xu J, Xu L Z, Long Z J, Wang X T, Li G H, Wan X Y, Yang Y L, Liu Q*(2015). Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget. (IF: 6.627).6(8):6326-6340.
-
. Zhou W, Xu J, Gelston E, Wu X, Zou Z, Wang B, Zeng Y, Wang H, Liu A, Xu L, Liu Q*(2015). Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells. Oncotarget. (IF: 6.627).6(25):21557-71.
-
. Zheng F, Yue C, Li G, He B, Cheng W, Wang X, Yan M, Long Z, Qiu W, Yuan Z, Xu J, Liu B, Shi Q, Lam EW, Hung MC,Liu Q*(2016). Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nat Commun. (IF: 10.742). 19;7:10180.
